alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Securities and Exchange Commission

          - [File No. 500-1]

It appears to the Securities and Exchange Commission that there is a lack of current and accurate information concerning the securities of Xtreme Motorsports International, Inc. (“Xtreme Motorsports”) because questions have arisen regarding trading in the company's stock. Xtreme Motorsports is quoted on the Pink Sheets under the symbol “XTMM.”

The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed company.

*Therefore, it is ordered,*                     pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of the above-listed company is suspended for the period from 9:30 a.m. EST, on March 3, 2010 through 11:59 p.m. EDT, on March 16, 2010.                

By the Commission.

Florence E. Harmon,

Deputy Secretary.

[FR Doc. 2010-4803 Filed 3-3-10; 4:15 pm]

BILLING CODE 8011-01-P
<PAGE>   1
                                                                      EXHIBIT 15

INDEPENDENT PUBLIC ACCOUNTANTS' AWARENESS LETTER

August 14, 1997

To the Board of Directors
of Essef Corporation
220 Park Drive
Chardon, Ohio

We have made a review, in accordance with standards established by the American
Institute of Certified Public Accountants, of the unaudited interim financial
information of Essef Corporation and Subsidiaries for the periods ended June 30,
1997 and 1996, as indicated in our report dated July 24, 1997; because we did
not perform an audit, we expressed no opinion on that information.

We are aware that our report referred to above, which is included in your
Quarterly Report on Form 10-Q for the quarter ended June 30, 1997, is
incorporated by reference in Registration Statement No. 33-17758 on Form S-8.

We also are aware that the aforementioned report, pursuant to Rule 436(c) under
the Securities Act of 1933, is not considered a part of the Registration
Statement prepared or certified by an accountant or a report prepared or
certified by an accountant within the meaning of Sections 7 and 11 of that Act.

DELOITTE & TOUCHE LLP

Cleveland, Ohio

                                  Page 17 of 17
Exhibit 10.13  


PRIVATE & CONFIDENTIAL  


To:
Bob Krakoff 



Date:
February 19, 1999 


Bob— 


        This
will confirm the terms of my severance arrangement with the Company as agreed at the time of my commencement of employment last September. 


        We
agreed that if I am terminated without "cause" (as defined in section 4(c) of my AHI Non-Qualified Stock Option Agreement dated September 8, 1998)
(i) before January 1, 2000, I will receive six months salary, target bonus and health benefits; (ii) on or after January 1, 2000 but before July 1, 2001, I will
receive nine months salary, target bonus and health benefits; and (iii) after July 1, 2001, I will receive twelve months salary, target bonus and health benefits. For the foregoing
severance purposes, relocation of my principal office location outside the greater Boston area without my consent will be tantamount to termination without cause. 


Agreed:



Advanstar
Holdings, Inc. 


Advanstar
Communications Inc. 


By
/s/  ROBERT L. KRAKOFF      


Name:
Robert L. Krakoff 


Title:
Chairman and CEO
STATE OF RHODE ISLAND AND PR OVIDENCE PLANTATIONS
COASTAL RESOURCES MANAGEMENT COUNCIL Oliver II . Stedman Government Center 4808 Tower Hill Road, Suite 3 Wakefield, R.I. 02879-1900

US Environmental Protection Agency Region 1 5 Post Office Square; Suite 100 Boston, MA 021 09 RE: CRMC File No. A2011-12-055 Dear Sirs/Madam: February 6, 2012 (40 1 ) 783-3370 FAX: (40 1) 783-3767

In accordance with Title 15 of the code of Federal Regulations, Part 930, subpart C (Consistency for Federal Activities) and review ofplans entitled: Vessel General Permit (VGP) and Small Ves sel General permit (sVGP) Request for Determination for Coastal Zone Management Program Consistency Determination. The Coastal Resources Managemeni Co unci l hereby concurs with the determination that the referenced project is consistent with the Federally approved Rhode Island Coastal Resources Management Council Program and applicable regulations th erein. j Please contact this office upon initiation of construction , o r if you s hould have any questions regarding this project.

/lat 

# s~£ Grover J. Fugj, 

# Ex~tor Coastal Resources Management Counc il
**Exhibit 31.2**

​

CERTIFICATION OF CHIEF FINANCIAL OFFICER (THE PRINCIPAL FINANCIAL OFFICER)

​

I, Michael Vesey, certify that:

​

1.I have reviewed this annual report on Form 10-K/A of Wayside Technology Group, Inc.; and

​
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

​

Date:  April 29, 2020

​

| ​                                                   | ​ |
|-----------------------------------------------------------|---------|
| /s/ Michael Vesey                                         | ​ |
| Michael Vesey                                             | ​ |
| Vice President                                            | ​ |
| and Chief Financial Officer (principal financial officer) | ​ |

​

​

----
<PAGE>   1
                       [CELLPRO INCORPORATED LETTERHEAD]


    Special advisory: This news release contains forward-looking statements.

            CELLPRO ANNOUNCES ASSET SALE AND DISTRIBUTION AGREEMENT;
          Resignation of Richard D. Murdock and Reduction in Workforce

SEATTLE -- September 28, 1998 - CellPro, Incorporated today announced that it
has executed a letter of intent to sell essentially all of its intangible assets
and intellectual property to Nexell Therapeutics, Inc., a subsidiary of VIMRx
Pharmaceuticals, Inc., for $3 million in VIMRx registered securities. CellPro
also agreed to appoint Baxter Healthcare Corporation as its exclusive worldwide
distributor of a limited number of disposable kits for its CEPRATE SC Stem Cell
Concentration System. Additionally, the company has agreed to settle all issues
remaining outstanding in its ongoing patent litigation with Baxter, John Hopkins
University and Becton Dickinson & Company for payments totaling approximately
$15.6 million.

The letter of intent contemplates that CellPro will discontinue all operations
other than the manufacturing and service functions necessary to support a
limited quantity of CEPRATE SC kits, intended to ensure the medical community
has continued access to stem cell selection technology. The letter of intent
also contemplates that consummation of the sale transaction will be conditioned
upon court approval of bankruptcy plan of reorganization to be filed promptly
after execution of definitive agreements. In connection with the announcements
made today, CellPro will discontinue its European operations. Workforce
reductions resulting from the announced transactions will affect approximately
93 employees worldwide, and include the resignation of Rick Murdock, President
and Chief Executive Officer.

Comments or forward-looking statements should be understood in the context of
CellPro's publicly available reports filed with the SEC, including the most
recent Annual Report on Form 10-K, which contain a discussion of various factors
that may affect CellPro's business. These factors could cause actual future
performance to differ materially from current expectations regarding future
performance, results or achievements. Particular attention should be given to
the Investment Considerations labeled "Future Capital Needs; Potential Inability
to Access Capital Markets; Possible Insolvency," "Legal Proceedings," "Parents
and Proprietary Technology" and "Dependence on CEPRATE(R) SC System," in
CellPro's Annual Report on Form 10-K for the fiscal year ended March 31, 1998
and to the Company's press release dated July 29, 1998.

Located in Bothell, Washington, CellPro, Incorporated is a biotechnology company
that develops, manufactures and markets proprietary continuous-flow,
cell-selection systems for use in a variety of therapeutic, diagnostic and
research applications. Its CEPRATE(R) SC System is being marketed in the United
States, Canada, the EC, Israel, Latin America and the Asia-Pacific.

                                      ###
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1215 Creatine phosphokinase/creatine kinase or isoenzymes test system. ( a ) *Identification.* A creatine phosphokinase/creatine kinase or isoenzymes test system is a device intended to measure the activity of the enzyme creatine phosphokinase or its isoenzymes (a group of enzymes with similar biological activity) in plasma and serum. Measurements of creatine phosphokinase and its isoenzymes are used in the diagnosis and treatment of myocardial infarction and muscle diseases such as progressive, Duchenne-type muscular dystrophy.
( b ) *Classification.* Class II.
This disposition is not appropriate for publication and is not precedent *

except as provided by 9th Cir. R. 36-3.

The panel unanimously concludes this case is suitable for decision **

without oral argument. See Fed. R. App. P. 34(a)(2).

NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

 FOR THE NINTH CIRCUIT

UNITED STATES OF AMERICA,

 Plaintiff - Appellee,

 v.

ALFONZO ROJAS-TENA,

 Defendant - Appellant.

No. 10-30291

D.C. No. 4:09-cr-00154-BLW

MEMORANDUM*

Appeal from the United States District Court

for the District of Idaho

B. Lynn Winmill, Chief Judge, Presiding

Submitted October 9, 2012** 

Before: RAWLINSON, MURGUIA, and WATFORD, Circuit Judges. 

Alfonzo Rojas-Tena appeals from his guilty-plea conviction and 70-month

sentence for conspiracy to distribute 50 grams or more of actual methamphetamine,

in violation of 21 U.S.C. §§ 841(a)(1) and 846. Pursuant to Anders v. California,

FILED

OCT 16 2012

MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS
2 10-30291

386 U.S. 738 (1967), Rojas-Tena’s counsel has filed a brief stating there are no

grounds for relief, along with a motion to withdraw as counsel of record. We have

provided Rojas-Tena the opportunity to file a pro se supplemental brief. No pro se

supplemental brief or answering brief has been filed.

Our independent review of the record pursuant to Penson v. Ohio, 488 U.S.

75, 80 (1988), discloses no arguable grounds for relief on direct appeal. We

dismiss in light of the valid appeal waiver. See United States v. Watson, 582 F.3d

974, 988 (9th Cir. 2009).

Counsel’s motion to withdraw is GRANTED.

DISMISSED.
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.1575 Titanium dioxide. ( a ) *Identity and specifications.* ( 1 ) The color additive titanium dioxide shall conform in identity and specifications to the requirements of § 73.575(a)(1) and (b).
( 2 ) Color additive mixtures for drug use made with titanium dioxide may contain only those diluents that are suitable and that are listed in this subpart as safe in color additive mixtures for coloring drugs, and the following: Silicon dioxide, SiO2, and/or aluminum oxide, Al2O3, as dispersing aids—not more than 2 percent total.
( b ) *Uses and restrictions.* The color additive titanium dioxide may be used for coloring ingested and externally applied drugs generally, in amounts consistent with good manufacturing practice. External application includes use in the area of the eye.
( c ) *Labeling.* The label of the color additive and any mixtures prepared therefrom and intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of the chapter.
( d ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health and therefore batches thereof are exempt from the certification requirements of section 721(c) of the act.
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3660 *Shigella* spp. serological reagents. ( a ) *Identification. Shigella* spp. serological reagents are devices that consist of antigens and antisera, including antisera conjugated with a fluorescent dye (immunofluorescent reagents), used in serological tests to identify *Shigella* spp. from cultured isolates. The identification aids in the diagnosis of shigellosis caused by bacteria belonging to the genus *Shigella* and provides epidemiological information on this disease. Shigellosis is characterized by abdominal pain, cramps, diarrhea, and fever.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 63 FR 59227, Nov. 3, 1998]
CONFIDENTIAL

These pages have been removed as TSCA Confidential Business Information.
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                                        <C>
<PERIOD-TYPE>                                    3-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1997  
<PERIOD-END>                               MAR-31-1997
<CASH>                                          21,800
<SECURITIES>                                         0
<RECEIVABLES>                                    8,200
<ALLOWANCES>                                         0
<INVENTORY>                                     33,300
<CURRENT-ASSETS>                                79,600
<PP&E>                                         993,700
<DEPRECIATION>                                 332,700
<TOTAL-ASSETS>                                 772,100
<CURRENT-LIABILITIES>                          239,400
<BONDS>                                        258,000
<PREFERRED-MANDATORY>                            1,800
<PREFERRED>                                          0
<COMMON>                                         1,000
<OTHER-SE>                                     254,000
<TOTAL-LIABILITY-AND-EQUITY>                   772,100
<SALES>                                         38,400
<TOTAL-REVENUES>                                38,400
<CGS>                                           25,200
<TOTAL-COSTS>                                   39,300
<OTHER-EXPENSES>                                 3,000
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               4,900<F1>
<INCOME-PRETAX>                                (6,100)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (6,100)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                        4,500
<NET-INCOME>                                   (1,600)
<EPS-PRIMARY>                                    (.03)
<EPS-DILUTED>                                    (.03)
<FN>
<F1>Net of interest income of $0.3 million and capitalized interest of $4.2 million
</FN>
        

</TABLE>
# C_2014380EN.01002602.xml

| 27.10.2014 | EN | Official Journal of the European Union | C 380/26 |
| --- | --- | --- | --- |

27.10.2014

EN

Official Journal of the European Union

C 380/26

---

Action brought on 17 July 2014 — ZZ v Council

(Case F-67/14)

2014/C 380/34

Language of the case: French

Parties

Parties

Applicant: ZZ (represented by: M. Velardo, lawyer)

Applicant:

Defendant: Council

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

Annulment of the decision to terminate the applicant’s employment at the end of his probationary period and compensation for the non-material harm allegedly suffered.

Form of order sought

Form of order sought

The applicant claims that the Tribunal should:

| — | annul the decision of 25 June 2013 of the Secretariat of the Council and the decision of 8 April 2014 of the appointing authority of the Council, by which the applicant’s employment was terminated; |
| --- | --- |

—

annul the decision of 25 June 2013 of the Secretariat of the Council and the decision of 8 April 2014 of the appointing authority of the Council, by which the applicant’s employment was terminated;

| — | order the defendant to pay, by way of damages, a sum calculated on the basis of the applicant’s monthly remuneration as a member of staff employed at Grade AST 3 (EUR 3  500) multiplied by the number of months expired between 1 July 2013 and the date of delivery of the judgment in the present case; |
| --- | --- |

—

order the defendant to pay, by way of damages, a sum calculated on the basis of the applicant’s monthly remuneration as a member of staff employed at Grade AST 3 (EUR 3  500) multiplied by the number of months expired between 1 July 2013 and the date of delivery of the judgment in the present case;

| — | order the defendant to pay EUR 40  000 in respect of the non-material harm suffered; |
| --- | --- |

—

order the defendant to pay EUR 40  000 in respect of the non-material harm suffered;

| — | order the defendant to pay the costs incurred by the applicant in the proceedings. |
| --- | --- |

—

order the defendant to pay the costs incurred by the applicant in the proceedings.

---
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.2300 Cardiac monitor (including cardiotachometer and rate alarm). ( a ) *Identification.* A cardiac monitor (including cardiotachometer and rate alarm) is a device used to measure the heart rate from an analog signal produced by an electrocardiograph, vectorcardiograph, or blood pressure monitor. This device may sound an alarm when the heart rate falls outside preset upper and lower limits.
( b ) *Classification.* Class II (performance standards).
§ 82.1255 D&C Orange No. 5. ( a ) The color additive D&C Orange No. 5 shall conform in identity and specifications to the requirements of § 74.1255(a)(1) and (b) of this chapter. D&C Orange No. 5 is restricted to the uses described in this section.
( b ) The color additive D&C Orange No. 5. may be safely used for coloring externally applied drugs in amounts not exceeding 5 milligrams per daily dose of the drug. The color additive D&C Orange No. 5 may be safely used for coloring lipsticks and other cosmetics intended to be applied to the lips in amounts not exceeding 5.0 percent by weight of the finished cosmetic products, and for coloring mouthwashes, dentifrices, and externally applied cosmetics in amounts consistent with current good manufacturing practice.
[49 FR 13343, Apr. 4, 1984]
§ 74.2330 D&C Red No. 30. ( a ) *Identity and specifications.* The color additive D&C Red No. 30 shall conform in identity and specifications to the requirements of § 74.1330 (a)(1) and (b).
( b ) *Uses and restrictions.* D&C Red No. 30 may be safely used for coloring cosmetics generally in amounts consistent with current good manufacturing practice.
( c ) *Labeling requirements.* The label of the color additive shall conform to the requirements of § 70.25 of this chapter.
( d ) *Certification.* All batches of D&C Red No. 30 shall be certified in accordance with regulations in part 80 of this chapter.
[47 FR 22511, May 25, 1982]
Exhibit 99(b)


        Written Statement of the Vice President Law/Finance and Secretary
                          Pursuant to 18 U.S.C. ss.1350

     Solely for the purposes of complying with 18 U.S.C. ss.1350, I, the
undersigned Vice President Law/Finance and Secretary of Ladish Co., Inc. (the
"Company"), hereby certify, based on my knowledge, that the Quarterly Report on
Form 10-Q/A of the Company for the quarter ended March 31, 2002 (the "Report")
fully complies with the requirements of Section 13(a) of the Securities Exchange
Act of 1934, and that information contained in the Report fairly presents, in
all material respects, the financial condition and results of operations of the
Company.




/s/  Wayne E. Larsen
----------------------------------------
Wayne E. Larsen
October 31, 2002
#### § 812.66 Significant risk device determinations.

If an IRB determines that an investigation, presented for approval under § 812.2(b)(1)(ii), involves a significant risk device, it shall so notify the investigator and, where appropriate, the sponsor. A sponsor may not begin the investigation except as provided in § 812.30(a).

[46 FR 8957, Jan. 27, 1981]